Bill

Bill > HR2087


US HR2087

Drug Price Transparency Act


summary

Introduced
04/04/2019
In Committee
04/05/2019
Crossed Over
Passed
Dead
12/31/2020

Introduced Session

116th Congress

Bill Summary

To amend title XVIII of the Social Security Act to require certain manufacturers to report drug pricing information with respect to drugs under the Medicare program, and for other purposes. This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

AI Summary

This bill, the Drug Price Transparency Act, requires certain manufacturers of drugs covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services (CMS). Specifically, manufacturers that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or report false information are subject to civil penalties. The bill also directs the Inspector General of the Department of Health and Human Services to assess and report on the accuracy of the average sales price information submitted by manufacturers.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (2)

Last Action

Subcommittee Hearings Held. (on 05/21/2019)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...